FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095334012> ?p ?o ?g. }

• W2095334012 endingPage "589" @default.
• W2095334012 startingPage "582" @default.
• W2095334012 abstract "Daptomycin is a therapeutic option for patients with underlying renal insufficiency who are vulnerable to nephrotoxicity from vancomycin. We evaluated the efficacy and safety of daptomycin in patients with renal impairment.Multicenter, retrospective, observational, case series analysis.Two academic medical centers.One hundred and sixty adults with creatinine clearance (Clcr ) of 50 ml/minute or less who received daptomycin for at least 72 hours for complicated Gram-positive infections from 2008-2011.Clinical and microbiologic outcomes were assessed at the end of daptomycin therapy. Safety evaluations were documented for all patients, and when available, creatine phosphokinase (CPK) levels were recorded. Thirty-eight (23.8%) patients were on hemodialysis, and 122 (76.3%) had a decreased baseline renal clearance not requiring hemodialysis with a median interquartile range (IQR) Clcr of 32.4 ml/minute (24.2-40.4 ml/min). The median (IQR) daptomycin dose was 6.0 mg/kg (5.8-7.8 mg/kg) administered every 24 hours in 68 patients (42.5%) and every 48 hours in 92 patients (57.5%). Daptomycin success, including cure or improvement, (Cure: signs and symptoms resolved and no additional antibiotic therapy required, or infection cleared with negative cultures reported at the end of daptomycin therapy; Improvement: partial resolution of signs and symptoms and additional antibiotic therapy necessary at the end of daptomycin therapy) was achieved in 128 of 160 (80.0%) patients at the end of therapy. Methicillin-resistant Staphylococcus aureus (MRSA) was the most common pathogen (45%) isolated. The most frequent reason for using daptomycin was due to vancomycin-associated nephrotoxicity (20%). Daptomycin therapy was discontinued in six patients (3.8%) because of elevated CPK (median time to onset, 11.5 days). Loss of daptomycin susceptibility occurred in two patients with complex endovascular infections who were on hemodialysis.Daptomycin demonstrated clinical and microbiologic success rates comparable with prior studies. Discontinuation of therapy because of elevated CPK levels may have been avoided in some patients with adjustment to every 48-hour dosing for Clcr less than 30 ml/minute. The relatively early time to onset suggests the need for CPK monitoring more frequently than once/week in renally impaired patients receiving daptomycin. The treatment of bacteremia in patients with renal insufficiency warrants further study." @default.
• W2095334012 created "2016-06-24" @default.
• W2095334012 creator A5010504597 @default.
• W2095334012 creator A5017445754 @default.
• W2095334012 creator A5070880383 @default.
• W2095334012 creator A5086036837 @default.
• W2095334012 date "2014-03-21" @default.
• W2095334012 modified "2023-10-06" @default.
• W2095334012 title "Efficacy and Safety of Daptomycin in Patients with Renal Impairment: A Multicenter Retrospective Analysis" @default.
• W2095334012 cites W1550111394 @default.
• W2095334012 cites W1978679680 @default.
• W2095334012 cites W1983960319 @default.
• W2095334012 cites W2002249283 @default.
• W2095334012 cites W2063172021 @default.
• W2095334012 cites W2069041533 @default.
• W2095334012 cites W2076664566 @default.
• W2095334012 cites W2098384416 @default.
• W2095334012 cites W2099481682 @default.
• W2095334012 cites W2099952421 @default.
• W2095334012 cites W2112505466 @default.
• W2095334012 cites W2117913801 @default.
• W2095334012 cites W2121121756 @default.
• W2095334012 cites W2122905476 @default.
• W2095334012 cites W2124285733 @default.
• W2095334012 cites W2131432189 @default.
• W2095334012 cites W2139101850 @default.
• W2095334012 cites W2139155301 @default.
• W2095334012 cites W2140147718 @default.
• W2095334012 cites W2144963218 @default.
• W2095334012 cites W2146341069 @default.
• W2095334012 cites W2148954461 @default.
• W2095334012 cites W2152771638 @default.
• W2095334012 cites W2156451821 @default.
• W2095334012 cites W2162139256 @default.
• W2095334012 cites W2165211392 @default.
• W2095334012 cites W4214754383 @default.
• W2095334012 cites W4239364330 @default.
• W2095334012 doi "https://doi.org/10.1002/phar.1413" @default.
• W2095334012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24658897" @default.
• W2095334012 hasPublicationYear "2014" @default.
• W2095334012 type Work @default.
• W2095334012 sameAs 2095334012 @default.
• W2095334012 citedByCount "23" @default.
• W2095334012 countsByYear W20953340122014 @default.
• W2095334012 countsByYear W20953340122015 @default.
• W2095334012 countsByYear W20953340122016 @default.
• W2095334012 countsByYear W20953340122017 @default.
• W2095334012 countsByYear W20953340122018 @default.
• W2095334012 countsByYear W20953340122019 @default.
• W2095334012 countsByYear W20953340122020 @default.
• W2095334012 countsByYear W20953340122021 @default.
• W2095334012 countsByYear W20953340122022 @default.
• W2095334012 crossrefType "journal-article" @default.
• W2095334012 hasAuthorship W2095334012A5010504597 @default.
• W2095334012 hasAuthorship W2095334012A5017445754 @default.
• W2095334012 hasAuthorship W2095334012A5070880383 @default.
• W2095334012 hasAuthorship W2095334012A5086036837 @default.
• W2095334012 hasConcept C119060515 @default.
• W2095334012 hasConcept C126322002 @default.
• W2095334012 hasConcept C141071460 @default.
• W2095334012 hasConcept C159641895 @default.
• W2095334012 hasConcept C167135981 @default.
• W2095334012 hasConcept C2778063415 @default.
• W2095334012 hasConcept C2778651397 @default.
• W2095334012 hasConcept C2778980435 @default.
• W2095334012 hasConcept C2779489039 @default.
• W2095334012 hasConcept C523546767 @default.
• W2095334012 hasConcept C54355233 @default.
• W2095334012 hasConcept C71924100 @default.
• W2095334012 hasConcept C86803240 @default.
• W2095334012 hasConceptScore W2095334012C119060515 @default.
• W2095334012 hasConceptScore W2095334012C126322002 @default.
• W2095334012 hasConceptScore W2095334012C141071460 @default.
• W2095334012 hasConceptScore W2095334012C159641895 @default.
• W2095334012 hasConceptScore W2095334012C167135981 @default.
• W2095334012 hasConceptScore W2095334012C2778063415 @default.
• W2095334012 hasConceptScore W2095334012C2778651397 @default.
• W2095334012 hasConceptScore W2095334012C2778980435 @default.
• W2095334012 hasConceptScore W2095334012C2779489039 @default.
• W2095334012 hasConceptScore W2095334012C523546767 @default.
• W2095334012 hasConceptScore W2095334012C54355233 @default.
• W2095334012 hasConceptScore W2095334012C71924100 @default.
• W2095334012 hasConceptScore W2095334012C86803240 @default.
• W2095334012 hasIssue "6" @default.
• W2095334012 hasLocation W20953340121 @default.
• W2095334012 hasLocation W20953340122 @default.
• W2095334012 hasOpenAccess W2095334012 @default.
• W2095334012 hasPrimaryLocation W20953340121 @default.
• W2095334012 hasRelatedWork W2044565499 @default.
• W2095334012 hasRelatedWork W2078444411 @default.
• W2095334012 hasRelatedWork W2106310886 @default.
• W2095334012 hasRelatedWork W2110928570 @default.
• W2095334012 hasRelatedWork W2136296616 @default.
• W2095334012 hasRelatedWork W2144963218 @default.
• W2095334012 hasRelatedWork W2157018267 @default.
• W2095334012 hasRelatedWork W2807625228 @default.
• W2095334012 hasRelatedWork W2921148263 @default.
• W2095334012 hasRelatedWork W3028811422 @default.

• next